-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
The American Society of Hematology (ASH) is the world's largest professional society focusing on the etiology and treatment of blood diseases.
It brings together top experts in this field and provides the latest information on hematological malignancies
.
According to public information, many new drugs developed or co-developed by Chinese companies will also be unveiled at this conference
.
Among them, Professor Song Yuqin, Department of Lymphatic Oncology, Peking University Cancer Hospital, published an abstract paper titled "Phase Ia Study of Dose Escalation of Anti-CD20 Antibody Conjugate Drug MRG001 in Relapsed/Refractory Advanced Non-Hodgkin's Lymphoma"
.
Before the start of the conference, we will first interpret the clinical data report of MRG001's Phase Ia study, and share the current progress in the treatment of non-Hodgkin's lymphoma (NHL) in China, to unveil the "veil" for the 63rd ASH Conference in advance
.
Prof.
Song Yuqin, Deputy Director, Chief Physician, and Doctoral Supervisor, Lymphoma Department, Peking University Cancer Hospital, Director, Chinese Society of Clinical Oncology (CSCO), Secretary-General, Chinese Society of Clinical Oncology (CSCO) Anti-Lymphoma Alliance, Chairman, Beijing Anti-Cancer Association, Lymphhaematological Oncology Committee Vice Chairman of the Lymphoma Hematological Oncology Committee of the Chinese Society of Geriatric Oncology Vice Chairman of the Lymphoma Professional Committee of the Chinese Geriatric Healthcare Association Member and Secretary of the Standing Committee of the Beijing Medical Association Oncology Professional Committee The annual meeting of the American Society of Hematology will be held online and offline in Atlanta, USA.
Hematology experts from all over the world will gather again to announce and publish the latest developments in hematology from all over the world
.
Important progress in the field of lymphoma is undoubtedly still focused on NHL
.
In recent years, antibody-conjugated drugs (ADC) have sprung up in the oncology field, combining the targeted delivery of monoclonal antibodies with the tumor-killing potential of payloads
.
ADC drugs have been on the market one after another, which has also brought good news to the treatment of NHL
.
CD20 is an antigen commonly expressed on the surface of B cells.
Using it as a target to tailor a suitable monoclonal antibody can defeat the enemy in one move.
Therefore, anti-CD20 monoclonal antibody drugs improve the remission rate of NHL
.
MRG001 is a CD20-targeted ADC drug with leading clinical progress.
It has the potential to be the first of its kind.
It is intended to treat CD20-positive relapsed or refractory B-cell NHL
.
At this ASH conference, Professor Song Yuqin published an abstract paper entitled "Phase Ia Study of Dose Escalation of Anti-CD20 Antibody Conjugation Drug MRG001 in Relapsed/Refractory Advanced Non-Hodgkin Lymphoma".
Here, we are the first to interpret Clinical data report of MRG001 Phase Ia study
.
MRG001 leads clinical progress.
MRG001 is an ADC drug that is made up of an anti-CD20 monoclonal antibody conjugated with a tubulin inhibitor, methyl auristatin E (MMAE) via a valine-citrulline linker
.
Currently, MRG001 is conducting an in vivo, open, multi-center phase I study to evaluate its safety, tolerability, and tolerance in patients with CD20-positive relapsed or refractory (R/R) B-cell NHL.
Pharmacokinetics (PK) and preliminary anti-tumor activity
.
The study is divided into two phases: dose escalation (Ia) and dose expansion (Ib)
.
As of May 31, 2021, a total of 21 subjects who met the inclusion criteria received MRG001 treatment, including diffuse large B-cell lymphoma (DLBCL) (n=8), follicular lymphoma (FL) (n= 12) Patients with marginal zone lymphoma (MZL) (n=1)
.
According to Frost & Sullivan's data, there is no marketed CD20 targeting antibody conjugate drug product in the world.
As a new drug for relapsed/refractory advanced non-Hodgkin's lymphoma, MRG001 has leading clinical progress and has the potential to be the first of its kind
.
It is expected that MRG001 will deliver an amazing answer sheet in the future.
In the initial dose of 0.
15 mg/kg, one FL subject achieved partial remission (PR)
.
Six subjects (4 DLBCL and 2 FL) were included in the 1.
8 mg/kg group.
One DLBCL subject achieved complete remission (CR), and the other DLBCL subject achieved PR.
Objective response rate (ORR) ) Was 33.
33% (2 out of 6 cases), 3 cases reached stable disease (SD), and the disease control rate (DCR) was 83.
3%
.
Three subjects were included in the 2.
5 mg/kg group, and two FL subjects achieved PR.
Although both had dose-limiting toxicity (DLT) in the first cycle, when the dose was reduced from the second cycle to 1.
8 mg/kg , ORR reached 66.
7% (2 out of 3 cases)
.
Among 21 patients, 1 (5%) CR, 4 (19%) PR, 9 (43%) SD and 7 (33%) disease progression (PD), the ORR of all dose groups was 24%, The DCR is 67%
.
This study shows that MRG001 has manageable safety and preliminary anti-tumor activity in NHL patients
.
According to the safety, tolerability and pharmacokinetic parameters of MRG001, the clinical phase II recommended dose (RP2D) is determined to be 1.
8 mg/kg, and the next step is to study it
.
Summary Most NHL patients are difficult to cure completely through existing treatments, and usually go through the process of "remission-relapse-remission-relapse".
This is the difficulty in the treatment of relapsed and refractory NHL
.
With the vigorous development of the domestic biopharmaceutical industry, more and more competitive innovative drugs have been born.
MRG001 is an emerging ADC drug independently developed by Meacco, a subsidiary of Lepu Biotech
.
Based on current clinical trials, MRG001 has shown the potential to overcome rituximab resistance and significant tumor growth inhibitory effects in patients with relapsed and refractory NHL
.
The future of NHL treatment will usher in a new world.
We firmly believe that as domestic pharmaceutical companies continue to innovate, more and more innovative drugs will be displayed and participate in international competition, and Chinese lymphoma patients will also have a better life.
Tomorrow! Poke "read the original text", we make progress together
It brings together top experts in this field and provides the latest information on hematological malignancies
.
According to public information, many new drugs developed or co-developed by Chinese companies will also be unveiled at this conference
.
Among them, Professor Song Yuqin, Department of Lymphatic Oncology, Peking University Cancer Hospital, published an abstract paper titled "Phase Ia Study of Dose Escalation of Anti-CD20 Antibody Conjugate Drug MRG001 in Relapsed/Refractory Advanced Non-Hodgkin's Lymphoma"
.
Before the start of the conference, we will first interpret the clinical data report of MRG001's Phase Ia study, and share the current progress in the treatment of non-Hodgkin's lymphoma (NHL) in China, to unveil the "veil" for the 63rd ASH Conference in advance
.
Prof.
Song Yuqin, Deputy Director, Chief Physician, and Doctoral Supervisor, Lymphoma Department, Peking University Cancer Hospital, Director, Chinese Society of Clinical Oncology (CSCO), Secretary-General, Chinese Society of Clinical Oncology (CSCO) Anti-Lymphoma Alliance, Chairman, Beijing Anti-Cancer Association, Lymphhaematological Oncology Committee Vice Chairman of the Lymphoma Hematological Oncology Committee of the Chinese Society of Geriatric Oncology Vice Chairman of the Lymphoma Professional Committee of the Chinese Geriatric Healthcare Association Member and Secretary of the Standing Committee of the Beijing Medical Association Oncology Professional Committee The annual meeting of the American Society of Hematology will be held online and offline in Atlanta, USA.
Hematology experts from all over the world will gather again to announce and publish the latest developments in hematology from all over the world
.
Important progress in the field of lymphoma is undoubtedly still focused on NHL
.
In recent years, antibody-conjugated drugs (ADC) have sprung up in the oncology field, combining the targeted delivery of monoclonal antibodies with the tumor-killing potential of payloads
.
ADC drugs have been on the market one after another, which has also brought good news to the treatment of NHL
.
CD20 is an antigen commonly expressed on the surface of B cells.
Using it as a target to tailor a suitable monoclonal antibody can defeat the enemy in one move.
Therefore, anti-CD20 monoclonal antibody drugs improve the remission rate of NHL
.
MRG001 is a CD20-targeted ADC drug with leading clinical progress.
It has the potential to be the first of its kind.
It is intended to treat CD20-positive relapsed or refractory B-cell NHL
.
At this ASH conference, Professor Song Yuqin published an abstract paper entitled "Phase Ia Study of Dose Escalation of Anti-CD20 Antibody Conjugation Drug MRG001 in Relapsed/Refractory Advanced Non-Hodgkin Lymphoma".
Here, we are the first to interpret Clinical data report of MRG001 Phase Ia study
.
MRG001 leads clinical progress.
MRG001 is an ADC drug that is made up of an anti-CD20 monoclonal antibody conjugated with a tubulin inhibitor, methyl auristatin E (MMAE) via a valine-citrulline linker
.
Currently, MRG001 is conducting an in vivo, open, multi-center phase I study to evaluate its safety, tolerability, and tolerance in patients with CD20-positive relapsed or refractory (R/R) B-cell NHL.
Pharmacokinetics (PK) and preliminary anti-tumor activity
.
The study is divided into two phases: dose escalation (Ia) and dose expansion (Ib)
.
As of May 31, 2021, a total of 21 subjects who met the inclusion criteria received MRG001 treatment, including diffuse large B-cell lymphoma (DLBCL) (n=8), follicular lymphoma (FL) (n= 12) Patients with marginal zone lymphoma (MZL) (n=1)
.
According to Frost & Sullivan's data, there is no marketed CD20 targeting antibody conjugate drug product in the world.
As a new drug for relapsed/refractory advanced non-Hodgkin's lymphoma, MRG001 has leading clinical progress and has the potential to be the first of its kind
.
It is expected that MRG001 will deliver an amazing answer sheet in the future.
In the initial dose of 0.
15 mg/kg, one FL subject achieved partial remission (PR)
.
Six subjects (4 DLBCL and 2 FL) were included in the 1.
8 mg/kg group.
One DLBCL subject achieved complete remission (CR), and the other DLBCL subject achieved PR.
Objective response rate (ORR) ) Was 33.
33% (2 out of 6 cases), 3 cases reached stable disease (SD), and the disease control rate (DCR) was 83.
3%
.
Three subjects were included in the 2.
5 mg/kg group, and two FL subjects achieved PR.
Although both had dose-limiting toxicity (DLT) in the first cycle, when the dose was reduced from the second cycle to 1.
8 mg/kg , ORR reached 66.
7% (2 out of 3 cases)
.
Among 21 patients, 1 (5%) CR, 4 (19%) PR, 9 (43%) SD and 7 (33%) disease progression (PD), the ORR of all dose groups was 24%, The DCR is 67%
.
This study shows that MRG001 has manageable safety and preliminary anti-tumor activity in NHL patients
.
According to the safety, tolerability and pharmacokinetic parameters of MRG001, the clinical phase II recommended dose (RP2D) is determined to be 1.
8 mg/kg, and the next step is to study it
.
Summary Most NHL patients are difficult to cure completely through existing treatments, and usually go through the process of "remission-relapse-remission-relapse".
This is the difficulty in the treatment of relapsed and refractory NHL
.
With the vigorous development of the domestic biopharmaceutical industry, more and more competitive innovative drugs have been born.
MRG001 is an emerging ADC drug independently developed by Meacco, a subsidiary of Lepu Biotech
.
Based on current clinical trials, MRG001 has shown the potential to overcome rituximab resistance and significant tumor growth inhibitory effects in patients with relapsed and refractory NHL
.
The future of NHL treatment will usher in a new world.
We firmly believe that as domestic pharmaceutical companies continue to innovate, more and more innovative drugs will be displayed and participate in international competition, and Chinese lymphoma patients will also have a better life.
Tomorrow! Poke "read the original text", we make progress together
